Roivant Sciences Hits New 52-Week High at $29.82, Up 179%

Roivant Sciences has reached a significant milestone by hitting a new 52-week high of USD 29.82 on March 4, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 179.02% rise over the past year, significantly outpacing the S&P 500's performance of 17.36% during the same period. As a mid-cap player in the Pharmaceuticals & Biotechnology industry, Roivant Sciences has a market capitalization of approximately USD 19,431 million. Despite its recent stock performance, the company is currently loss-making, with a negative return on equity of -26.15%. The stock's price-to-book ratio stands at 4.55, indicating how the market values the company's equity relative to its book value. The company's financial metrics also reveal a debt-to-equity ratio of -1.06, suggesting a unique capital structure. With no dividend yield reported, Roivant Sciences continues to focus on its growth trajectory within the competitive pharmaceutical landscape. The achievement of this 52-week high underscores the stock's notable activity and performance in the market.